Business Wire

ETA

19.5.2023 18:55:34 CEST | Business Wire | Press release

Share
Egypt: A Family-Friendly Exotic Destination

If you are planning a family holiday, look no further than Egypt. The country is renowned for its all-inclusive hotels and resorts that cater to the needs of families with children. These resorts offer entertainment programs and excursions suitable for all age groups. Museums and cultural sights also offer family-friendly activities. Furthermore, Egypt's warm temperatures and dry climate throughout the year make it an ideal destination for holidays all year round, with sandy beaches and shallow water that are sure to excite children.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005234/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Family Holiday in Egypt (Photo: Business Wire)

What Makes a Holiday Family-Friendly?

A holiday is meant to be a time for relaxation, escaping everyday life and enjoying oneself. However, this can be challenging when traveling with children. Egypt's all-inclusive hotels and resorts provide stress-free options for families with children. The resorts offer animation programs for children of different ages, with pools featuring water slides and children's pools. In addition, multilingual caretakers are available to look after children when parents want to pursue their own plans undisturbed for an afternoon or evening. This allows parents to relax and enjoy their holiday with peace of mind.

Activities for the whole Family

There are many activities that families can enjoy together in Egypt. Clubs and resorts offer a range of sports activities, including mini golf, beach football, and volleyball. For those interested in water activities like diving, snorkelling, or kite surfing, there are beginner courses as well as special children's courses available.

In the cities itself, families can find a variety of activities like water parks, amusement parks, safari tours, and aquariums. Additionally, museums can be a great way to make history exciting for children, with the Egyptian Museum in Cairo offering guided tours specifically designed for kids. Outside of the cities, families can have adventures like desert tours in buggies or riding on camels. Compared to similar activities in Europe, leisure activities in Egypt are much more affordable, allowing families to experience more together or take some time for themselves to relax.

"Nile Trips and Abu Simbel"

Aswan, the southernmost city in Egypt, is located directly on the Nile, making it an excellent starting point for interesting and varied tours. Visitors can take Nile trips to the temples of Kom Ombo and even further north to Luxor. Close to the city lies Lake Nasser, at the southern end of which stands the spectacular temple complex of Abu Simbel. The four 20-metre-high statues of Pharaoh Ramses II at the main entrance of the temple are an incomparable sight and rightly rank among the most popular sights in the country.

Aswan itself is also full of treasures to discover, such as the Agha Khan Mausoleum on the west bank of the Nile, or the archaeological Nubian Museum that highlights the history of the Nubian population, who make up a large part of Aswan's inhabitants. The city also includes numerous islands in the Nile, such as Elephantine Island, or Kitchener Island to the north, where the city's botanical garden can be found.

Background information on the Egyptian Tourism Authority
The Egyptian Tourism Authority (ETA) was established in 1981 to boost international tourism by highlighting Egypt's long history and traditional civilization and promoting the country and its many tourist attractions. ETA's mission also includes promoting domestic tourism, raising awareness of tourism throughout the country, and strengthening the connection between Egyptians and their heritage.

The ETA's focus is on the one hand on the diversity of attractions and destinations within Egypt, and on the other hand on developing marketing strategies and programs to promote tourism, as well as providing technical and marketing support. It also organizes and sponsors tourism, sports, and social and cultural events throughout the country. The ETA Board of Directors is chaired by the Minister of Tourism.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005234/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye